TEJAS-2
Phase 2 Terminated
29 enrolled
Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors
Phase 1 Terminated
34 enrolled
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
Phase 1 Terminated
115 enrolled 43 charts
PRO1107 in Patients With Advanced Solid Tumors
Phase 1/2 Terminated
33 enrolled
A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.
Phase 1 Terminated
10 enrolled
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
Phase 1/2 Terminated
73 enrolled
Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies
Phase 1 Terminated
17 enrolled
NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
Phase 1 Terminated
82 enrolled
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Phase 1/2 Terminated
137 enrolled 31 charts
A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors
Phase 1 Terminated
10 enrolled
A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors
Phase 1 Terminated
9 enrolled
NM32-2668 in Adult Patients With Selected Advanced Solid Tumors
Phase 1 Terminated
11 enrolled
AM-003
Phase 1 Terminated
5 enrolled
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
Phase 1 Terminated
221 enrolled
Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.
Phase 1 Terminated
85 enrolled
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
Phase 2 Terminated
54 enrolled 11 charts
A Phase 1/2 Study of VIO-01 in Participants With Recurrent Solid Tumors
Phase 1/2 Terminated
6 enrolled
A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer
Phase 1 Terminated
133 enrolled
A Study of SGN-ALPV in Advanced Solid Tumors
Phase 1 Terminated
43 enrolled
A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.
Phase 1 Terminated
127 enrolled
Milademetan in Advanced/Metastatic Solid Tumors
Phase 2 Terminated
40 enrolled 13 charts
Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors
Phase 1/2 Terminated
7 enrolled
Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors
Phase 1 Terminated
37 enrolled 32 charts
Study of RO7515629 in Participants With HLA-G Positive Solid Tumors
Phase 1 Terminated
3 enrolled
Study of ADCT-301 in Patients With Selected Advanced Solid Tumors
Phase 1 Terminated
78 enrolled 39 charts
ORCHID-1
Phase 1/2 Terminated
26 enrolled
A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors
Phase 1/2 Terminated
47 enrolled 11 charts
Study of PF-07263689 in Participants With Selected Advanced Solid Tumors
Phase 1 Terminated
13 enrolled 16 charts
A Study of PY314 in Subjects With Advanced Solid Tumors
Phase 1 Terminated
86 enrolled
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
Phase 1 Terminated
24 enrolled
A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR)
Phase 1/2 Terminated
25 enrolled 11 charts
A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies
Phase 1 Terminated
87 enrolled
A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours
Phase 1/2 Terminated
6 enrolled
A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors
Phase 1 Terminated
10 enrolled
LODESTAR
Phase 2 Terminated
83 enrolled 16 charts
Sacral Nerve Stimulation in Treating Low Anterior Resection Syndrome or Fecal Incontinence in Patients With Locally Advanced Rectal Cancer or Other Pelvic Cancer, the RESTORE Study
Phase 2 Terminated
3 enrolled 5 charts
ALpha-T
Phase 2 Terminated
1 enrolled 5 charts
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
Phase 1/2 Terminated
7 enrolled 9 charts
NTX-301 Monotherapy in Advanced Solid Tumours and in Combination With Platinum-based Chemotherapy in Advanced Ovarian & Bladder Cancer and in Combination With Temozolomide in High-grade Glioma
Phase 1/2 Terminated
12 enrolled
A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer
Phase 2 Terminated
111 enrolled 15 charts
Neoadjuvant Immunotherapy in Brain Metastases
Phase 2 Terminated
1 enrolled 7 charts
Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell Tumors
Phase 2 Terminated
12 enrolled 14 charts
Safety Study of MGD009 in B7-H3-expressing Tumors
Phase 1 Terminated
67 enrolled
INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
Phase 1/2 Terminated
10 enrolled 14 charts
MK-6018-001
Phase 1 Terminated
27 enrolled
A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma
Phase 1 Terminated
16 enrolled
HYPAZ
Phase 2 Terminated
31 enrolled
A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6)
Phase 1 Terminated
21 enrolled
T Cells in Predicting Acute Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant
Terminated
150 enrolled
N1
Terminated
23 enrolled